ArticlePsychopharmacology2010
Contribution of limbic norepinephrine to cannabinoid-induced aversion.
Article in Psychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Stress reactivity is modulated by cannabinoid type-1 receptors in norepinephrine and epinephrine neurons in a context-dependent manner.Neuroscience · 2025Article
- Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.Experimental neurology · 2017Article
- Repeated administration of a synthetic cannabinoid receptor agonist differentially affects cortical and accumbal neuronal morphology in adolescent and adult rats.Brain structure & function · 2016Article
- Cannabinoid abuse and addiction: Clinical and preclinical findings.Clinical pharmacology and therapeutics · 2015Review
- Chronic alcohol exposure differentially affects activation of female locus coeruleus neurons and the subcellular distribution of corticotropin releasing factor receptors.Progress in neuro-psychopharmacology & biological psychiatry · 2015Article
- Endocannabinoid signaling in the etiology and treatment of major depressive illness.Current pharmaceutical design · 2014Review
- Interaction between Antagonist of Cannabinoid Receptor and Antagonist of Adrenergic Receptor on Anxiety in Male Rat.Basic and clinical neuroscience · 2014Article
- Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.Neuroscience · 2013Review
- Noradrenergic alpha-2 receptor modulators in the ventral bed nucleus of the stria terminalis: effects on anxiety behavior in postpartum and virgin female rats.Behavioral neuroscience · 2013Article
- Modulating the modulators: interaction of brain norepinephrine and cannabinoids in stress.Experimental neurology · 2012Article
- Effects of noradrenergic alpha-2 receptor antagonism or noradrenergic lesions in the ventral bed nucleus of the stria terminalis and medial preoptic area on maternal care in female rats.Psychopharmacology · 2012Article
- Stress-induced sensitization of cortical adrenergic receptors following a history of cannabinoid exposure.Experimental neurology · 2012Article
- Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders.Progress in neuro-psychopharmacology & biological psychiatry · 2012Review
- Direct intra-accumbal infusion of a beta-adrenergic receptor antagonist abolishes WIN 55,212-2-induced aversion.Neuroscience letters · 2011Article
- Interactions between brainstem noradrenergic neurons and the nucleus accumbens shell in modulating memory for emotionally arousing events.Learning & memory (Cold Spring Harbor, N.Y.) · 2011Article
- Hindbrain noradrenergic A2 neurons: diverse roles in autonomic, endocrine, cognitive, and behavioral functions.American journal of physiology. Regulatory, integrative and comparative physiology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
rationaleThe cannabinoid system has risen to the forefront in the development of novel treatments for a number of pathophysiological processes. However, significant side effects have been observed in clinical trials raising concerns regarding the potential clinical utility of cannabinoid-based agents. Understanding the neural circuits and neurochemical substrates impacted by cannabinoids will provide a better means of gaging their actions within the central nervous system that may contribute to the expression of unwanted side effects.
objectivesIn the present study, we investigated whether norepinephrine (NE) in the limbic forebrain is a critical determinant of cannabinoid receptor agonist-induced aversion and anxiety in rats.
methodsAn immunotoxin lesion approach was combined with behavioral analysis using a place conditioning paradigm and the elevated zero maze.
resultsOur results show that the non-selective CB1/CB2 receptor agonist, WIN 55,212-2, produced a significant place aversion in rats. Further, NE in the nucleus accumbens was critical for WIN 55,212-2-induced aversion but did not affect anxiety-like behaviors. Depletion of NE from the bed nucleus of the stria terminalis was ineffective in altering WIN 55,212-2-induced aversion and anxiety.
conclusionsThese results indicate that limbic, specifically accumbal, NE is required for cannabinoid-induced aversion but is not essential to cannabinoid-induced anxiety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.